EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc ... in combination with mycophenolate mofetil (MMF) to treat lupus nephritis (LN). The Company’s collaboration partner, Otsuka ...

The REGENCY study met its primary endpoint, demonstrating statistically significant and clinically meaningful treatment benefits in people with active lupus nephritis – – Gazyva is designed to ...

“We are thrilled to achieve this milestone that will provide access to LUPKYNIS in Japan, where there is a high rate of lupus nephritis among Japanese lupus patients. Our successful strategic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...

Regular assessment of renal function, proteinuria, and serological markers is crucial for monitoring lupus nephritis progression and treatment response. Long-term follow-up data offer valuable ...

Drug interactions, patient characteristics, and steroid use are critical in LN management, influencing treatment choices and outcomes. Nephrologists focus on renal preservation, while ...

The Lupus Research Institute (LRI) today announced the first $1 million research grants given to lupus investigators by a private research organization. The LRI Distinguished Innovator Initiative was ...

Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN). Gazyva is an engineered humanized monoclonal antibody ...

Paul Hoover, M.D., Ph.D., Brigham and Women’s Hospital Lupus nephritis is a severe kidney disease affecting many people with lupus and often leads to kidney failure. Dr. Hoover helped discover a ...